Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus
Complicaciones digestivas y renales por indometacina e ibuprofeno en prematuros extremos con ductus arterioso permeable
| dc.contributor | en-US | |
| dc.contributor | es-ES | |
| dc.creator | Salas, Rodrigo | |
| dc.creator | Lavín, Pablo | |
| dc.creator | Rincón, Yohanna | |
| dc.creator | Miranda, Juan | |
| dc.creator | López, María | |
| dc.date | 2017-06-05 | |
| dc.identifier | http://www.revistachilenadepediatria.cl/index.php/rchped/article/view/238 | |
| dc.description | Introduction: The symptomatic patent ductus arteriosus (sPDA) is common in extremely premature infants (EPI). In order to decrease the hemodynamic repercussion and avoid complications it is necessary to close it. Indomethacin or ibuprofen are used for this purpose with its associated risks.Objective: Characterize digestive and renal complications in EPI who received indomethacin or ibuprofen as sPDA treatment.Patients and Method: Retrospective study on EPI between January-2004 and December-2013. Three groups were compared: treated with indomethacin or ibuprofen and a non-treated group. EPI with other serious complications were excluded. The primary outcomes on each group were digestive and/or renal complications. Statistical significance was p < 0.05.Results: 599 EPI were included, 33.1% with PDA received treatment and 66.9% did not need it. A statistical association was found between sPDA and lower gestational ages, neonatal depression and respiratory distress. In the non-treated group, 5% presented enterocolitis and 0.25% renal failure; on the treated group, 2.5% presented enterocolitis and 1.0% renal failure. No significant differences were found between the treated and non-treated groups in relation to complications considering enterocolitis (p = 0.11) or renal failure (p = 0.33) alone, or combined (p = 0.17). No difference were detected either between those treated with indomethacin or ibuprofen.Conclusions: The results show that in absence of other clinical complication, medical treatment of sPDA with indomethacin or ibuprofen, do not increase the risk of serious digestive or renal disorders. There were no advantages of using indomethacin or ibuprofen over the other. | en-US |
| dc.description | Introducción: El ductus arterioso permeable sintomático (DAPs) es frecuente en prematuros extremos (PE), siendo importante su cierre para disminuir la repercusión hemodinámica. Para ello se usa indometacina o ibuprofeno con los riesgos subyacentes.Objetivo: Caracterizar las complicaciones digestivas y renales en PE tratados por DAPs.Pacientes y Método: Estudio retrospectivo en PE nacidos entre enero de 2004 y diciembre de 2013. Según diagnóstico se distribuyeron en 3 grupos: sin DAPs, con DAPs tratados con indometacina y con ibuprofeno. Se excluyeron PE con otras complicaciones graves. Se evaluaron complicaciones digestivas y renales graves. Se usó significación estadistica con p = 0,05.Resultados: Se enrolaron 599 PE; 33,1% recibió tratamiento por DAPs, 66,9% no lo requirió. Hubo asociación estadística entre DAPs y menor edad gestacional, depresión neonatal y distrés respiratorio. Del grupo no tratado, el 5% presentó enterocolitis y el 0,25% falla renal; entre los tratados el 2,5% presentó enterocolitis y el 1,0% falla renal. No hubo diferencias estadísticas significativas considerando ambas complicaciones (p = 0,17), sólo enterocolitis (p = 0,11) o sólo falla renal (p = 0,33) entre tratados y no tratados; tampoco las hubo al comparar complicaciones entre tratados con indometacina o ibuprofeno.Conclusiones: Los resultados en nuestra población demuestran que el tratamiento médico del DAPs, en ausencia de otras complicaciones clínicas, no representa un mayor riesgo de complicaciones graves digestivas o renales. No se demostraron ventajas entre la indometacina e ibuprofeno. | es-ES |
| dc.format | application/pdf | |
| dc.format | application/pdf | |
| dc.language | spa | |
| dc.language | eng | |
| dc.publisher | Sociedad Chilena de Pediatría | es-ES |
| dc.relation | http://www.revistachilenadepediatria.cl/index.php/rchped/article/view/238/89 | |
| dc.relation | http://www.revistachilenadepediatria.cl/index.php/rchped/article/view/238/126 | |
| dc.rights | Copyright (c) 2017 Revista Chilena de Pediatría | es-ES |
| dc.source | Revista Chilena de Pediatría; Vol. 88, Núm. 2 (2017): Marzo - Abril; 243-251 | en-US |
| dc.source | Andes Pediatrica; Vol. 88, Núm. 2 (2017): Marzo - Abril; 243-251 | es-ES |
| dc.source | 2452-6053 | |
| dc.source | 2452-6053 | |
| dc.subject | en-US | |
| dc.subject | Patent Ductus Arteriosus; Premature Infants; Indomethacin; Ibuprofen; Enterocolitis; Pharmacology; Cardiology; Adverse Drug Reaction | en-US |
| dc.subject | es-ES | |
| dc.subject | Ductus Arterioso Permeable; Prematuros; Indometacina; Ibuprofeno; Enterocolitis; Farmacología; Cardiología; Reacción Adversa a Fármacos y Drogas; Ductus Arterioso Persistente | es-ES |
| dc.title | Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus | en-US |
| dc.title | Complicaciones digestivas y renales por indometacina e ibuprofeno en prematuros extremos con ductus arterioso permeable | es-ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | en-US | |
| dc.type | es-ES |
This item appears in the following Collection(s)
-
Revista Chilena de Pediatría
[0-9]{4}